Keyphrases
Pulmonary Artery
100%
Right Ventricular Hypertrophy
100%
GW0742
100%
PPAR Agonists
100%
Hypoxia-induced Pulmonary Hypertension
100%
Pulmonary Hypertension
50%
Prostacyclin
33%
Rat Model
16%
Clinical Trials
16%
Endothelin Receptor Antagonist
16%
Target Receptor
16%
Aortic Tissue
16%
Genetically Engineered Mice
16%
Dilators
16%
Clinical Benefit
16%
Therapeutic Benefits
16%
Hyperpolarization
16%
RhoA Activity
16%
Oral Dosing
16%
Hypoxia
16%
Etiology
16%
Current Therapies
16%
Pulmonary Arterial Hypertension
16%
Difficult-to-treat
16%
Relaxation Effect
16%
Right Ventricular Systolic Pressure
16%
Pulmonary Vascular Disease
16%
Clinical Evidence
16%
Vasorelaxation
16%
IP Receptor
16%
Vascular Remodeling
16%
New Treatment Options
16%
Clinical Conditions
16%
Cell Surface
16%
Phosphodiesterase Type 5 Inhibitors
16%
Non-associated
16%
Cyclic GMP
16%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Hypertrophy
100%
Hypoxia-Induced Pulmonary Hypertension
100%
[4 [2 (3 Fluoro 4 Trifluoromethylphenyl) 4 Methyl 5 Thiazolylmethylthio] 2 Methylphenoxy]acetic Acid
100%
PPAR Agonist
100%
Pulmonary Hypertension
66%
Prostacyclin
33%
Receptor
33%
Peroxisome Proliferator Activated Receptor
16%
Endothelin Receptor Antagonist
16%
Pulmonary Vascular Disease
16%
Clinical Trial
16%
Phosphodiesterase V Inhibitor
16%
Rat Model
16%
Genetically Engineered Mouse Strain
16%
Vascular Remodeling
16%
Hypoxia
16%